GB2211737A - Aqueous formulations of piperidinylcyclopentylheptenoic acid derivatives - Google Patents
Aqueous formulations of piperidinylcyclopentylheptenoic acid derivatives Download PDFInfo
- Publication number
- GB2211737A GB2211737A GB8829793A GB8829793A GB2211737A GB 2211737 A GB2211737 A GB 2211737A GB 8829793 A GB8829793 A GB 8829793A GB 8829793 A GB8829793 A GB 8829793A GB 2211737 A GB2211737 A GB 2211737A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- cyclodextrin
- hydrochloride salt
- formulation
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Description
AQUEOUS FORMULATIONS CONTAINING A
PIPERIDINYLCYCLOPENTYLHEPTENOIC ACID DERIVATIVE
This invention relates to aqueous formulations containing as active ingredient ElR-(la(Z),2,3p,5a])-(+)-7-E5-t(l,l1-biphenyl)- 4-yllmethoxy]-3-hydroxy-2-(l-piperidinyl acid (hereinafter referred to as 'Compound A'), to processes for their preparation and to their use in medicine.
Compound A is described in our British patent No. 2097397 as one of a group of aminocyclopentane derivatives having endoperoxide and thromboxane antagonist activity, and it is reported therein that such compounds are of interest in the treatment of asthma and cardiovascular diseases. More recently, we discovered that the hydrochloride salt of Compound A has advantages over Compound A and other salts and solvates thereof both in its preparation and in its use in medicine. The hydrochloride salt is described in our British
Patent No. 2127406.
Compound A is unfortunately only sparingly soluble in water and formulations in water containing the hydrochloride salt of Compound A together with standard excipients and/or carriers have proved to be unacceptable for intravenous administration as the hydrochloride salt of Compound A is converted to the virtually insoluble Compound A at near to physiological pH.
We have now found that the solubility in water of Compound A or its hydrochloride salt at around physiological pH is significantly improved in the presence of an unsubstituted or substituted a-, ss~ or y-cyclodextrin (or a hydrate thereof). We have also found that aqueous formulations comprising Compound A or the hydrochloride salt thereof and an unsubstituted qr substituted a-, ss- or y-cyclodextrin (or a hydrate thereof) are suitable for use in medicine, more particularly for use in the treatment or prophylaxis of conditions mediated by thromboxane A2, when administered either orally, by inhalation or parenterally, in particular by injection (eg intravenously).
Thus, according to one aspect of the present invention, we provide an aqueous formulation comprising Compound A or the hydrochloride salt thereof with an unsubstituted or substituted a-, t3-, or y-cyclodextrin (or a hydrate thereof).
In another aspect of the invention, we provide an aqueous formulation as defined herein for use in medicine, more particularly for use in the treatment or prophylaxis of conditions mediated by thromboxane A2.
According to another aspect of the invention, we provide a method of treating conditions mediated by thromboxane A2 which method comprise administering to the human or animal patient an effective amount of Compound A in an aqueous formulation as defined herein.
Suitable conditions which may be treated with aqueous formulations of the present invention include those conditions described in British Patents Nos. 2097397 and 2127406 treated using other (e.g. oral) formulations of Compound A and the hydrochloride salt of Compound A respectively. In particular, the aqueous formulations of the present invention may be used in the treatment or prophylaxis of occlusive vascular disease, including myocardial infarction, cardiac fatalities, unstable angina, transient ischaemic attacks and cerebral infarction, atherosclerosis and vessel wall disease, peripheral vascular disease, retinopathy, postoperative thrombosis and pulmonary embolism.The aqueous formulations may also be used in the prophylaxis of peri- and postoperative complications following organ transplantation (particularly cardiac and renal), coronary artery bypass, peripheral artery bypass and thrombolysis.
The aqueous formulations are also of potential use in connection with peptic ulcer disease, more particularly for the prevention of relapse of healed peptic ulcers.
Preferably, in the aqueous formulations of the present invention Compound A is used as its hydrochloride salt.
It will be appreciated by those skilled in the art that the benefits of the present invention may be achieved by utilising more than one cyclodextrin, although the use of a single cyclodextrin is generally preferred.
Where a substituted cyclodextrin is employed any suitable substituted cyclodextrin known in the art may be used according to the present invention. Suitable substituted cyclodextrins for use according to the present invention will be readily appreciated by persons skilled in the art and will include sulphur-containing cyclodextrins, nitrogen-containing cyclodextrins, alkylated (e.g.
methylated) cyclodextrins such as mono-, di- or trimethylated derivatives of a cyclodextrin (e.g. of B-cyclodextrin) and hydroxyalkyl (e.g. hydroxypropyl) cyclodextrins such as hydroxypropyl p-cyclodextrin and acylated derivatives thereof. Hydroxyalkyl (e.g.
hydroxypropyl) cyclodextrins such as hydroxypropyl B-cyclodextrin have been found to be particularly suitable for use according to the present invention.
Conveniently a single unsubstituted cyclodextrin is employed according to the present invention. Particularly preferred is ss-cyclodextrin, conveniently used in its hydrated form.
In order for the aqueous formulation to exhibit the desired properties it is important that the correct molar ratio-of Compound A or its hydrochloride salt to the cyclodextrin(s) is used. We have found a molar ratio of Compound A or its hydrochloride salt to the cyclodextrin(s) within the range 1:1 to 1:4 to be suitable.
It will be appreciated by persons skilled in the art that the aqueous formulations of the present invention may, if desired, also contain one or more pharmaceutical carriers or excipients.
Suitable excipients which may be incorporated into the aqueous formulation include agents to make the preparation isotonic with blood plasma (e.g. sodium chloride, dextrose or preferably mannitol) and buffering agents (e.g. phosphate buffer or a mixture of sodium acid phosphate and disodium phosphate).
The aqueous formulations of the present invention are particularly suitable for parenteral administration in particular by injection (eg intravenously). When presented for parenteral administration it is desirable that the formulation is at about physiological pH. It may therefore be appropriate to adjust the pH to about physiological pH using conventional means, for example using a suitable base such as a hydroxide (e.g. an alkali metal hydroxide such as sodium hydroxide solution). Conveniently, the pH is adjusted to about pH 6.0.
For parenteral administration, in particular for administration by injection (eg intravenously), it is highly desirable for the formulation to be presented as a clear solution. A clear solution requires no further processing (e.g. constitution of a dry powder) and may be administered without delay. The use of a clear solution also ensures that the product can be easily inspected for particulate or other visible contamination. Furthermore, intravenous injection of an aqueous solution of a drug can produce an immediate physiological action. We have found that at least one mole of the cyclodextrin must be used for every one mole of the hydrochloride of Compound A in order to obtain a clear solution at near to physiological pH at normal storage temperatures, and in the case of ss-cyclodextrin at least about 1.2 moles must be used.
In a preferred embodiment of the present invention, therefore, we provide a clear aqueous formulation comprising the hydrochloride salt of Compound A and p-cyclodextrin (or a hydrate thereof), at about physiological pH wherein the formulation contains at least about 1.2 moles of ss-cyclodextrin (e.g. 1.2 to 2 moles) for every one mole of the hydrochloride salt of Compound A. Preferably the molar ratio will be about 1:1.4.
The concentration of Compound A or the hydrochloride salt thereof in the aforementioned aqueous formulations suitable for parenteral administration, in particular for administration by injection (eg intravenously), is conveniently within the range O.l-lOmg/ml, e.g.
O.l-5mg/ml, expressed as the free base. Preferably, the concentration is lmg/ml expressed as the free base when the aqueous formulation is administered by intravenous injection. If desired, a higher concentration may be used and the solution may be diluted prior to use with, for example, an isotonic saline solution or dextrose or mannitol solution. Conveniently, solutions suitable for injection are presented in an appropriate dose volume (eg 1 - 100 ml). Dilutions suitable for continuous infusion may have a concentration of Compound
A or its hydrochloride salt of 0.01 - 0.2mg/ml expressed as the free base.The solution for continuous infusion may be presented in this form, for example in packs of 50-lOOml, or may be presented in more concentrated forms for subsequent dilution before use with, for example, an isotonic saline solution or dextrose or mannitol solution. Alternatively, small volumes of a more concen rated solution (eg 0.1 - 5 mg/ml) may be utilised for continuos infusion conveniently administered at a rate of 0.5 to 9.9ml/h.
The aqueous formulations described herein may conveniently be prepared by mixing Compound A or, more preferably, its hydrochloride salt with the remaining constituents in water. Preferably, Compound A or its hydrochloride salt are dissolved in water and the remaining constituents are added thereto. For parenteral administration, in particular by injection (eg intravenously), the bulk solution is preferably filtered, then filled into suitable containers and terminally sterilised, for example by heating. Alternatively, the solution may be sterilised by filtration and then aseptically filled into suitable containers.
It will be appreciated that water suitable for injection will be used when the parenteral formulation is to be administered intravenously or by continuous infusion.
Formulations for injection may be presented in unit dose form in suitable containers such as ampoules, vials or pre-filled syringes, or in multi-dose containers with an added preservative.
As stated hereinbefore, the aqueous formulations of the present invention are also suitable for oral administration (eg as a capsule, syrup or solution) or for administration by inhalation (eg as an aerosol spray conveniently presented as a nebuliser). British Patent
Nos. 2097397 and 2127406 provide suitable general methods for the preparation of oral and inhalation formulations which may be readily adapted without undue experimentation for present purposes.
Aqueous formulations may also be prepared by dissolving a solid cyclodextrin complex of Compound A or its hydrochloride salt in water together, where desirable, with one or more other constituents as defined above.
Thus, in a further aspect of the present invention, we provide an aqueous formulation comprising a complex of Compound A or the hydrochloride salt thereof and a cyclodextrin.
In another aspect of the invention, we provide a complex of
Compound A or its hydrochloride salt and a cyclodextrin. The ratio of
Compound A or the hydrochloride salt of Compound A with the cyclodextrin in the said complex will, of course, vary considerably depending on the cyclodextrin used and the conditions employed for preparing the complex. However, we have found a molar ratio of
Compound A or its hydrochloride salt with the cyclodextrin within the range 1:1 to 1:3 to be suitable.
The cyclodextrin employed in the solid complex may be unsubstituted or substituted a-, ss- or y-cyclodextrin as defined previously or may be a mixture of such cyclodextrins (e.g a mixture of two such cyclodextrins). Preferably y-cyclodextrin or, more preferably, 8-cyclodextrin is employed.
In a particular aspect of the present invention we provide a complex of Compound A and ss-cyclodextrin in which the molar ratio of
Compound A to ss-cyclodextrin is within the range 1:1 to 1:2, and is preferably about 1:1.
In another particular aspect of the present invention we provide a complex of Compound A and y-cyclodrextrin in which the molar ratio of Compound A to y-cyclodextrin is about 1:1.5.
Complexes of Compound A or the hydrochloride salt thereof and cyclodextrin may be prepared by mixing Compound A or its hydrochloride salt with the cyclodextrin(s) or a hydrate thereof in a suitable solvent under conditions whereby the desired complex is formed. Thus, for example, the complexes may be prepared by dissolving Compound A or it hydrochloride salt in water or an organic solvent which is miscible with water (e.g. an alcohol such as methanol) and adding to the solution a solution of the appropriate cyclodextrin(s) or a hydrate thereof in water and/or an organic solvent which is miscible with water.The reaction may be effected at a temperature in the range of Oo to 8O0C; however the mixture is preferably kept at around room temperature and the desired complex obtained by concentrating the mixture under reduced pressure or by allowing the mixture to cool.
The mixing ratio of organic solvent with water may vary considerably according to the solubilities of the starting materials and products.
Preferably 1 to 4 moles of cyclodextrin are used for each mole of
Compound A or its hydrochloric salt.
The resulting complexes may be obtained as white solids with high thermal stability and good water solubility. Such physical characteristics make them particularly suitable for formulation into pharmaceutical preparations for medical use. In addition to the aforementioned aqueous formulations of complexes of Compound A or its hydrochloride salt and cyclodextrin suitable particularly for parenteral administration, the complexes may also be formulated for oral or parenteral administration or for administration by inhalation according to the general methods described in British Patent Nos.
2097397 and 2127406.
An appropriate daily dose regime for Compound A or its hydrochloride salt when employed in one of the formulations of the present invention will, of course, depend on the specific condition to be treated, the age and condition of the patient and the route of administration. However, generally the dosages quoted in British
Patent Nos. 2097397 and 2127406 will be suitable.
The following examples are included by way of illustrating the present invention and should not be construed as a limitation of the invention. In the following examples the molar ratios were determined by 'H N.M.R. analysis and all temperatures are in 00.
Example 1 (a) [lR1a(Z),2,3,5a]](+)7[5-((i,11-Biphenyl)-4-yl]methoxy]-3 hydroxy-2-(1-piperidinyl)cyclopenty1]-4-heptenoate: B- cy clodextrin (1:1) complex ss-Cyclodextrin hydrate (û.954g) was nearly completely dissolved in water (35ml). The suspension was filtered and the filtrate added to a solution of Compound A (0.2g, Example 10 in GB-B-2097397) in methanol (lOml). The reaction solution was stirred at 210 for 26h to give a clear solution which was evaporated to a volume of 12ml when slight crystallisation began to occur.The suspension was cooled to 50 for lh to produce a thick precipitate which was filtered off and dried to give the title compound (0.2739), m.p. > 3100, darkens above 2300.
(b) The filtrate from the above experiment began to precipitate more crystalline material on standing and was therefore evaporated to leave a white solid which was dissolved in hot water (3ml), cooled (50) and allowed to crystallise to give a white crystalline solid (121mg) shown by 1H N.M.R. (DMSO) analysis to contain [1R-[1α(Z),2ss,3ss,5α]]-(+)-7- t5-rt(l,l'-biphenyl)-4-yl]methoxy]-3-hydroxe-2-(1-piperidinyl)- cyclopentyll-4-heptenoate : ss-cyclodextrin (1:1.5) complex.
Example 2 [1R-[1α(Z),2ss,3ss,5α]]-(+)-7-[5-[[(1,1'-Biphenyl)-4-yl]methoxy]-3 hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoate: -cyclodextrin (1:1.5) complex
A solution of y-cyclodextrin (1.099) in water (25ml) was added to a solution of Compound A (0.209) in methanol (lOml). The reaction solution was stirred at 210 for 26h to produce a thick white suspension. The precipitate was filtered off and dried in vacuo to leave the title compound as a white solid (0.6129), m.p. > 3100, darkens above 2500.
Pharmaceutical examples of parenteral injections/infusions (i) Hydrochloride salt of Compound A
equivalent to 50 mg base ss-Cyclodextrin hydrate 143mg 166mg 238mg
Sodium hydroxide solution to pH7 to pH7 to pH7
Water suitable for injection to 50ml to 50ml to 50ml
The hydrochloride salt of Compound A was dissolved in 35ml water suitable for injection and the ss-cyclodextrin was added. This solution was titrated to pH7 with 0.02M sodium hydroxide solution and then adjusted to volume with water suitable for injection.
The solution may then be sterilised by filtration and filled into vials or ampoules.
(ii) Hydrochloride salt of Compound A
equivalent to 50mug base p-Cyclodextrin hydrate 166mg
Sodium chloride 450mg pH7.0 phosphate buffer 2.5ml
Sodium hydroxide solution to pH7
Water suitable for injection to 5ûml The hydrochloride salt of Compound A was dissolved in approximately 25ml water suitable for injection. The -cyclodextrin was dissolved therein and the resulting solution was titrated to pH6 with 0.02M sodium hydroxide solution and the phosphate buffer added. The sodium chloride was added to the solution and the pH adjusted to pH7 with sodium hydroxide. The solution was made up to volume with water suitable for injection. A sample of this solution was filled into a glass vial which was sealed with a rubber plug and metal overseal.
This was then autoclaved.
(iii) Hydrochloride salt of Compound A
equivalent to 50 mg base Hydroxypropyl-B-cyclodextrin 170mug Mannitol 2.59
pH 6.0 phosphate buffer 5.0ml Sodium hydroxide solution to pH 6
Water suitable for injection to 50ml
;The hydrochloride salt of Compound A was dissolved in approximately 25ml water suitable for injection and the hydroxypropyl-ss-cyclodextrin was added. The mannitol was then. added and the solution titrated to pH 6 with 0.02M sodium hydroxide solution. The phosphate buffer solution was added and the solution adjusted to volume with water suitable for injection. The solution was then filtered and filled into glass vials which were sealed with rubber plugs and metal overseals. These were then autoclaved.
(iv) Hydrochloride salt of Compound A
equivalent to 50mug base ss-Cyclodextrin hydrate 166mg
Mannitol 2.59
Sodium acid phosphate 46mg
Disodium phosphate, anhydrous 5mg
Sodium hydroxide solution to pH 6
Water suitable for injection . to 5ûml The hydrochloride salt of Compound A was dissolved in approximately 25ml water suitable for injection. The & yclodextrin and mannitol were dissolved therein and the solution titrated to pH 6 with 0.02M sodium hydroxide solution. The sodium acid phosphate and an hydros disodium phosphate were dissolved in water suitable for injection. This solution was added to the bulk solution which was made up to volume with water suitable for injection.The solution was filtered and filled into glass ampoules which were sealed and then autoclaved.
(v) Cyclodextrin
Mixture
a y ss + Y Hydrochloride salt of Compound A equivalent to 50mg base
Cyclodextrin 143mg l90mg 119mg 136mg
Mannitol 2.59 2.59 2.59 pH 6.0 Phosphate buffer 5.0ml 5.0ml 5.0ml Sodium hydroxide solution to pH 6 to pH 6 to pH6
Water suitable for injection to 50ml to 50 ml to 50ml
The hydrochloride salt of Compound A was dissolved in approximately 25ml water suitable for injection and the cyclodextrin(s) was (were) added. The mannitol was then added and the solution titrated to pH 6 with 0.02M sodium hydroxide solution. The phosphate buffer solution was added and the solution was adjusted to volume with water suitable for injection. The solution was then filtered and filled into glass vials which were sealed with rubber plugs and metal overseals.
Pharmaceutical example of oral syrup
Hydrochloride salt of Compound A equivalent to 2.5mg base p-cyclodextrin hydrate 9mg
Citric acid to pH 4.5
Methyl hydroxybenzoate sodium 5mg
Propyl hydroxybenzoate sodium 2mg
Liquid orange flavour qs
Sucrose . 3.259
Purified water to 5.Oml
Dissolve the sucrose in a minimum quantity of water. Add the hydrochloride salt of Compound A and then the ss-cyclodextrin with stirring; adjust the pH to 4.5 with citric acid. With continued stirring add a solution of the hydroxybenzoates and lastly the flavour. Adjust almost to volume with water and stir. Check the pH and adjust to 4.5 with citric acid if necessary. Make up to volume with water.
Pharmaceutical example of solution for inhalation
Per 2ml dose
Hydrochloride salt of Compound A equivalent to 2mg base ss-cyclodextrin hydrate 7mg
Sodium chloride 18mg
Sodium hydroxide solution to pH 7.2 pH 7.2 phosphate buffer 0.2ml
Water suitable for injection to 2ml
Dissolve the hydrochloride salt of Compound A in water suitable for injection. Dissolve the ss-cyclodextrin therein and titrate the resulting solution to pH6 with sodium hydroxide solution; add the phosphate buffer solution. Add the sodium chloride and adjust to pH7.2 with sodium hydroxide solution. Make the solution up to volume with water suitable for injection and sterilize the solution by filtration. Fill aseptically into containers suitable for inhalation by nebulising.
Claims (13)
1. An aqueous formulation comprising [1R-[1α(Z),2ss,3ss,5α])-(+)-7-[5- tt(lyl'-biphenyl)-4-yl]methoxy]-3-hydroxy-2-(1-piperidinyl) cyclopentyl3-4-heptenoic acid (Compound A) or the hydrochloride salt thereof with an unsubstituted or substituted a-, ss- or -cyclodextrin or a hydrate thereof.
2. A formulation as claimed in claim 1 wherein Compound A is used as its hydrochloride salt.
3. A formulation as claimed in claim 1 or claim 2 wherein the cyclodextrin is ss-cyclodextrin.
4. A formulation as claimed in any preceding claim in a form suitable for injection.
5. A clear aqueous formulation as claimed in claim 4 comprising the hydrochloride salt of Compound A and p-cyclodextrin or a hydrate thereof at about physiological pH wherein the formulation contains at least about 1.2 moles of ss-cyclodextrin for every one mole of the hydrochloride salt of Compound A.
6. A formulation as claimed in claim 5 wherein the molar ratio of the hydrochloride salt of Compound A to ss-cyclodextrin is about 1:1.4.
7. A formulation as claimed in any of claims 4-6 in which the pH is about pH 6.0.
8. A formulation as claimed in any of claims 4-7 also comprising sodium hydroxide.
9. A formulation as claimed in any of claims 4-8 having a concentration of 0.1-5mg/ml Compound A or the hydrochloride salt thereof expressed as the free base.
10. A formulation as claimed in any of claims 4-8 in a form suitable for continuous infusion having B concentration of 0.01-0.2 mg/ml
Compound A or the hydrochloride salt thereof expressed as the free base.
11. A process for the preparation of a formulation as claimed in any preceding claim which comprises mixing Compound A or its hydrochloride salt with the remaining constituents in water.
12. A complex of Compound A or its hydrochloride salt and an unsubstituted or substituted a-, ss- or y-cyclodextrin.
13. A complex of Compound A and ss-cyclodextrin in which the molar ratio of Compound A to ss-cyclodextrin is about 1:1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878729823A GB8729823D0 (en) | 1987-12-22 | 1987-12-22 | Complexes |
| GB888804422A GB8804422D0 (en) | 1988-02-25 | 1988-02-25 | Complexes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8829793D0 GB8829793D0 (en) | 1989-02-15 |
| GB2211737A true GB2211737A (en) | 1989-07-12 |
| GB2211737B GB2211737B (en) | 1991-12-11 |
Family
ID=26293226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8829793A Expired - Fee Related GB2211737B (en) | 1987-12-22 | 1988-12-21 | Aqueous formulations containing a piperidinylcyclopentylheptenoic acid derivative |
Country Status (29)
| Country | Link |
|---|---|
| JP (1) | JPH02210A (en) |
| KR (1) | KR890009402A (en) |
| CN (1) | CN1034132A (en) |
| AT (1) | AT395943B (en) |
| AU (1) | AU615245B2 (en) |
| BE (1) | BE1001704A3 (en) |
| CA (1) | CA1328078C (en) |
| CH (1) | CH676665A5 (en) |
| DE (1) | DE3843059A1 (en) |
| DK (1) | DK712888A (en) |
| ES (1) | ES2011727A6 (en) |
| FI (1) | FI885920A (en) |
| FR (1) | FR2624731B1 (en) |
| GB (1) | GB2211737B (en) |
| GR (1) | GR880100854A (en) |
| HU (1) | HU204700B (en) |
| IE (1) | IE61995B1 (en) |
| IL (1) | IL88764A0 (en) |
| IT (1) | IT1224835B (en) |
| LU (1) | LU87411A1 (en) |
| MY (1) | MY103952A (en) |
| NL (1) | NL8803126A (en) |
| NO (1) | NO885689L (en) |
| NZ (1) | NZ227446A (en) |
| PH (1) | PH24982A (en) |
| PL (1) | PL276595A1 (en) |
| PT (1) | PT89301B (en) |
| SE (1) | SE502288C2 (en) |
| ZW (1) | ZW18088A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015648A (en) * | 1988-06-21 | 1991-05-14 | Glaxo Group Limited | Use of a thromboxane receptor antagonist in pregnancy-induced hypertension and related conditions |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU616571B2 (en) * | 1988-10-28 | 1991-10-31 | Shiseido Company Ltd. | Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin |
| IT1269578B (en) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSISTING OF AN ACID TYPE DRUG, A CYCLODESTRINE AND A BASE. |
| KR100825736B1 (en) * | 2005-12-07 | 2008-04-29 | 한국전자통신연구원 | Apparatus for providing XML signnature in mobile environment and method thereof |
| KR100832740B1 (en) * | 2007-01-17 | 2008-05-27 | 한국과학기술원 | Mutant microorganism with improved productivity of branched amino acid and method for preparing it using the same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2097397A (en) * | 1981-04-29 | 1982-11-03 | Glaxo Group Ltd | Aminocyclopentanol acids and esters as prostaglandin analogues and their preparation and pharmaceutical formulation |
| GB2127406A (en) * | 1982-09-16 | 1984-04-11 | Glaxo Group Ltd | Piperidinylcyclopentanolheptenoic acid salt |
| WO1985002767A1 (en) * | 1983-12-21 | 1985-07-04 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS503362B1 (en) * | 1970-06-10 | 1975-02-04 | ||
| JPS5443569B2 (en) * | 1972-07-05 | 1979-12-20 | ||
| HU181703B (en) * | 1980-05-09 | 1983-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents |
| JPS58116423A (en) * | 1981-12-28 | 1983-07-11 | Sumitomo Chem Co Ltd | Methanoprostacycline pharmaceutical composition |
| JPS58192821A (en) * | 1982-04-30 | 1983-11-10 | Dainippon Pharmaceut Co Ltd | Remedy for anoxia of cranial nerve cells |
| JPS5946228A (en) * | 1982-09-08 | 1984-03-15 | Zeria Shinyaku Kogyo Kk | Preparation of water-soluble and lymph-transitional drug containing biologically active organic compound |
| JPS5973576A (en) * | 1982-09-16 | 1984-04-25 | グラクソ・グル−プ・リミテツド | Piperidinylcyclopentanolheptanoate |
| JPS60150039A (en) * | 1984-01-17 | 1985-08-07 | Minolta Camera Co Ltd | Amphibious fixed-focus camera |
| DE3504044A1 (en) * | 1985-02-04 | 1986-08-07 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 9-HALOGEN PROSTAGLANDIN CLATHRATE AND THEIR USE AS A MEDICINAL PRODUCT |
| JPS6327440A (en) * | 1986-07-18 | 1988-02-05 | Sanraku Inc | Glucosylated branched cyclodextrin-containing composition |
-
1988
- 1988-12-21 GR GR880100854A patent/GR880100854A/en unknown
- 1988-12-21 AU AU27356/88A patent/AU615245B2/en not_active Ceased
- 1988-12-21 FR FR8816902A patent/FR2624731B1/en not_active Expired - Fee Related
- 1988-12-21 FI FI885920A patent/FI885920A/en not_active Application Discontinuation
- 1988-12-21 IE IE382088A patent/IE61995B1/en not_active IP Right Cessation
- 1988-12-21 BE BE8801423A patent/BE1001704A3/en not_active IP Right Cessation
- 1988-12-21 KR KR1019880017106A patent/KR890009402A/en not_active Application Discontinuation
- 1988-12-21 HU HU886537A patent/HU204700B/en not_active IP Right Cessation
- 1988-12-21 DE DE3843059A patent/DE3843059A1/en not_active Ceased
- 1988-12-21 NZ NZ227446A patent/NZ227446A/en unknown
- 1988-12-21 PH PH37963A patent/PH24982A/en unknown
- 1988-12-21 PL PL27659588A patent/PL276595A1/en unknown
- 1988-12-21 DK DK712888A patent/DK712888A/en not_active Application Discontinuation
- 1988-12-21 GB GB8829793A patent/GB2211737B/en not_active Expired - Fee Related
- 1988-12-21 LU LU87411A patent/LU87411A1/en unknown
- 1988-12-21 JP JP63320759A patent/JPH02210A/en active Pending
- 1988-12-21 CH CH4758/88A patent/CH676665A5/de not_active IP Right Cessation
- 1988-12-21 CA CA000586606A patent/CA1328078C/en not_active Expired - Fee Related
- 1988-12-21 SE SE8804607A patent/SE502288C2/en not_active IP Right Cessation
- 1988-12-21 IT IT8848702A patent/IT1224835B/en active
- 1988-12-21 ZW ZW180/88A patent/ZW18088A1/en unknown
- 1988-12-21 NO NO88885689A patent/NO885689L/en unknown
- 1988-12-21 ES ES8803876A patent/ES2011727A6/en not_active Expired - Fee Related
- 1988-12-21 CN CN88108916A patent/CN1034132A/en active Pending
- 1988-12-21 NL NL8803126A patent/NL8803126A/en not_active Application Discontinuation
- 1988-12-21 AT AT0313088A patent/AT395943B/en not_active IP Right Cessation
- 1988-12-21 PT PT89301A patent/PT89301B/en not_active IP Right Cessation
- 1988-12-22 MY MYPI88001508A patent/MY103952A/en unknown
- 1988-12-22 IL IL88764A patent/IL88764A0/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2097397A (en) * | 1981-04-29 | 1982-11-03 | Glaxo Group Ltd | Aminocyclopentanol acids and esters as prostaglandin analogues and their preparation and pharmaceutical formulation |
| GB2127406A (en) * | 1982-09-16 | 1984-04-11 | Glaxo Group Ltd | Piperidinylcyclopentanolheptenoic acid salt |
| WO1985002767A1 (en) * | 1983-12-21 | 1985-07-04 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
Non-Patent Citations (3)
| Title |
|---|
| Chem. Pharm. Bull.,28(7), 1975-80 (1 * |
| J. Pharm. Sci. 67(12), 1665-8 (1978) * |
| JP56/150039 A2 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015648A (en) * | 1988-06-21 | 1991-05-14 | Glaxo Group Limited | Use of a thromboxane receptor antagonist in pregnancy-induced hypertension and related conditions |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0206490B1 (en) | Antibiotic clathrates | |
| SK6062003A3 (en) | Freeze-dried pantoprazole preparation and pantoprazole injection | |
| JPS62252749A (en) | Water soluble meglumine complex and glucamine salt, manufacture and medicinal composition | |
| EP0555693A1 (en) | Method of producing highly watersoluble cyclodextrin complex | |
| KR101731155B1 (en) | Stabilized voriconazole composition | |
| JP2009504746A (en) | Cyclodextrin inclusion complex of factor Xa inhibitor | |
| TW585764B (en) | Pharmaceutical composition comprising a nucleotide analogue and one or more glass forming additives | |
| US4036954A (en) | Stable prostaglandin E group-containing formulation | |
| US5942510A (en) | Pharmaceutical composition containing lamotrigine | |
| AU615245B2 (en) | Aqueous formulations containing a piperidinylcyclopentylheptenoic acid derivative | |
| US5221695A (en) | Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin | |
| US4968673A (en) | Use of a thromboxane receptor antagonist in renal diseases and dysfunction | |
| CN111514147B (en) | Levosimendan sodium medicinal composition for acute decompensated heart failure symptoms and preparation method thereof | |
| CA2486571C (en) | Pharmaceutical composition | |
| JPS6146454B2 (en) | ||
| JPS61171421A (en) | Production of stable prostaglandin e preparation | |
| JPH0343251B2 (en) | ||
| US5015648A (en) | Use of a thromboxane receptor antagonist in pregnancy-induced hypertension and related conditions | |
| KR20140053952A (en) | Composition comprising pyrazino-triazine derivatives | |
| JP3990728B2 (en) | N- [4-oxo-2- (1H-tetrazol-5-yl) -4H-1-benzopyran-8-yl] -4- (4-phenylbutoxy) benzamide salt | |
| WO2019180072A1 (en) | Parenteral pharmaceutical composition comprising neladenoson bialanate | |
| AU2006235847C1 (en) | Lyophilized pantoprazole preparation | |
| EP0342030A2 (en) | Use of a thromboxane receptor antagonist to complement arterial surgery | |
| FR2660309A1 (en) | NOVEL COMPLEXES OF TIAPROFENIC ACID OR ITS INSOLUBLE OR PARTIALLY SOLUBLE ESTERS WITH CYCLODEXTRINS OR DERIVATIVES THEREOF. | |
| JPH07157440A (en) | Composition for medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19961221 |